| 股票代码 | 603127 | 当期评分 | ||||
| 股票名称 | 昭衍新药 | |||||
| 报告日期 | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-09-30 | 2020-09-30 |
| 每股经营现金流(¥) | -- | 1.4671 | 1.5312 | 0.9157 | 0.9883 | ✘ |
| 销售净利润率(%) | 21.3778 | 25.3739 | 26.4647 | 27.8726 | 18.5597 | ✔ |
| 销售毛利率(%) | 49.5724 | 55.2099 | 52.2397 | 52.0034 | 49.0297 | ✔ |
| 净资产收益率(%) | 19.89 | 13.71 | 16.63 | 21.58 | 12.19 | ✘ |
| 营业增长率(%) | 17.0371 | 24.5957 | 35.6876 | 56.4047 | 81.2323 | ✔ |
| 净利润增长率(%) | 5.12 | 47.8861 | 41.5204 | 64.7253 | 54.2738 | ✔ |
| 每股收益(%) | 0.84 | 1.12 | 0.94 | 1.11 | 0.52 | ✔ |
| 现金流量比率(%) | 47.1113 | 38.5387 | 43.03 | 30.6721 | 31.5666 | ✔ |
| 三项费用比重(%) | 27.117 | 27.2956 | 19.5953 | 16.5213 | 23.9763 | ✔ |
| 每股净资产(¥) | 4.24 | 6.8146 | 5.6639 | 5.1109 | 4.2806 | ✔ |
| 流动比率(%) | 0.9561 | 1.9186 | 1.686 | 1.3269 | 1.2646 | ✔ |
| 速动比率(%) | 0.7009 | 1.6224 | 1.406 | 0.9117 | 0.7802 | ✘ |
| 现金比率(%) | 52.6133 | 129.9386 | 36.3381 | 36.6506 | 36.6506 | ✔ |
| 总资产利润率(%) | 9.5812 | 9.9414 | 10.3912 | 13.9269 | 7.2855 | ✔ |
| 主营利润比重% | 196.4732 | 178.0586 | 167.0269 | 161.4933 | 232.6377 | ✔ |
| 应收账款(万元) | 1,731.78 | 2,641.02 | 3,874.14 | 10,636.85 | 7,723.68 | ✔ |
| 应收票据(万元) | 189.96 | 300.29 | 605.59 | 191.14 | 174.54 | ✔ |
| 预付款项(万元) | 711.73 | 499.62 | 887.48 | 715.68 | 3,031.07 | ✔ |
| 存货(万元) | 6,437.50 | 9,223.66 | 11,455.99 | 20,048.13 | 34,388.12 | ✘ |
| 在建工程(万元) | 5,709.83 | 4,916.42 | 7,958.62 | 3,530.65 | 3,457.75 | ✘ |
| 应付款项(万元) | 1,946.13 | 1,293.04 | 2,013.05 | 4,369.83 | 6,449.33 | ✔ |
| 长期借款(万元) | -- | -- | -- | 917.50 | 2,396.53 | ✔ |
| 未分配利润(万元) | 12,853.25 | 20,276.60 | 28,215.28 | 41,014.13 | 47,350.87 | ✔ |
| 商誉(万元) | -- | -- | -- | 13,396.20 | 13,077.24 | ✔ |
| 流动资产(万元) | 35,591.61 | 34,342.50 | 45,150.99 | 77,717.30 | 90,197.18 | ✔ |
| 流动负债(万元) | 25,221.59 | 31,139.11 | 40,919.24 | 48,282.43 | 70,987.90 | ✔ |
昭衍新药603127评分结果 | 75.76分 | 买入/增持 | ||||